Nov 30, – Dec 2, 2011 Therapeutic Area Partnerships

Westin Copley Place
Boston, MA

TA Partnerships delivers companies offering the high-value assets that your future sales demand – plus, you’ll also meet the companies who are looking for exactly the assets you have to offer. The most active in-licensors and out-licensors will all be on hand to create future growth through investments in partnership deals.

If you attend one meeting this year, don’t waste your time picking through hundreds of irrelevant partners. Choose TA Partnerships 2011, whose pharmaceutical, biotechnology and investor attendees are the most senior-level in the business. Space is limited, so register today!

Featured Keynote Session and Case Study

When Bad Things Happen to Good Companies: Responding and Repositioning for Success

Conference Snapshot

  • A uniquely focused meeting among R&D, financing and business development leadership to improve the partnering process and encourage innovative thinking about productivity and dealmaking
  • Gain insights to pick targets and compounds likely to succeed)
  • Identify the right drugs and the right partners
  • Therapeutic Area challenges and opportunities: Who will win, Who won’t, and Where are you in the mix
  • Expert advisers and strategic decision-makers help make sure your company is one of the winners
  • Independent experts select the ten most promising clinical programs available for partnering in oncology, neuroscience, cardiovascular and metabolic, autoimmune and inflammatory, infectious disease and hot space therapeutic area tracks
  • Discover ways to finance Innovation and innovate dealmaking
  • What new ways of thinking can break down barriers to new medicines and how can partnering and financing drive the process?

Who Should Attend?

Biotech CEOs, Strategic Alliances, Business and Corporate Development, Commercial Analytics & Decision Support, Licensing, Global Discovery Alliance, Financial Planning & Analysis, Alliance Management, Venture Capital, Bankers & Service Providers

For more information, click here.

The comments are closed.